Data Sheet 1_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

“…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”

Data Sheet 2_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

“…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”

Data Sheet 3_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

“…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”

Data Sheet 4_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

“…Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. …”

Data_Sheet_1_Out-of-Hospital Cervical Ripening With a Synthetic Hygroscopic Cervical Dilator May Reduce Hospital Costs and Cesarean Sections in the United States—A Cost-Consequence... by Sita J. Saunders (8060075)

“…The cesarean-section rate was decreased by 3.78 percentage points (23.28% decreased to 19.50%). …”

DataSheet_1_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-... by Rafaella F. Q. Grenfell (12841457)

“…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”

Table_3_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”

Table_2_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”

Table_4_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”

Table_1_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Background<p>Effective and safe vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical to controlling the COVID-19 pandemic and will remain the most important tool in limiting the spread of the virus long after the pandemic is over.…”

Weighted size (kDa) of RNase A, RNase B, and DNase I. by Tonya M. Santaus (5559077)

MARS model for classification of seropositive/chagasic subjects. by Nisha Jain Garg (102122)

Normalized (relative to maximum = 100%) knee extensor forces as a function of time. by Ziad Abusara (848106)

“…(b) 50% of muscular loading (n = 7), the cartilage-on-cartilage space reached zero and cartilage thickness decreased for these loading conditions. …”

The mechanism for pattern convergence and divergence requires a high-threshold transfer function. by Gaia Tavoni (5451656)

Interactive Effects of Nitrogen and Phosphorus on Soil Microbial Communities in a Tropical Forest by Lei Liu (5074)

Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer by Kelly Coffey (129302)

“…Although an authentic sample of 4-methyl-5-bromoisothiazole was inactive against Tip60, in an <em>in vitro</em> HAT assay, 1,2-bis(isothiazol-5-yl)disulfane (NU9056) was identified as a relatively potent inhibitor (IC₅₀ 2 µM). …”

The S-DNA produced in the B-to-S transition does not promote RecA nucleoprotein filament formation. by Hongxia Fu (423266)

“…<p>(A) Time traces of the extension of an 876 bp DNA tether with two GC-rich ends recorded during B-to-S transition in force-increase scan and the reverse S-to-B transition in the subsequent force-decrease scan in 50 mM KCl, 10 mM MgCl₂, pH 7.4, at 24°C. …”

MARS model for classification of chagasic subjects exhibiting clinical disease. by Nisha Jain Garg (102122)

MVEC-EVs promoted OPC survival, proliferation, and motility in a dose-dependent manner. by Masashi Kurachi (106280)

“…(A) The proportion of pyknotic nuclei decreased at doses ≥ 50 μg/ml. …”

Percentage of open AMPA receptors after the release of a single vesicle of glutamate. by Jesus Montes (436513)